FoleyR.N., ParfreyP.S., SarnakM.J.Clinical epidemiology of cardiovascular disease in chronic renal failure.Am J Kidney Dis1998; 32(Suppl 5): S112–19.
2.
RossR.Atherosclerosis: an inflammatory disease.N Engl J Med1999; 340: 115–26.
3.
BergströmJ., HeimbürgerO., LindholmB., QureshiA.R.Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients (Abstract).J Am Soc Nephrol1995; 6: 573.
4.
ZimmermannJ., HerrlingerS., PruyA., MetzgerT., WannerC.Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.Kidney Int1999; 55: 648–58.
5.
IsekiK., TozawaM., YoshiS., FukiyamaK.Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients.Nephrol Dial Transplant1999; 14: 1956–60.
6.
YeunJ.Y., LevineR.A., MantadilokV., KaysenG.A.C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients.Am J Kidney Dis2000; 35: 469–76.
7.
NohH., LeeS.W., KangS.W., ShinS.K., ChoiK.H., LeeH.Y.Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients.Nephrol Dial Transplant1998; 18: 387–94.
8.
HaubitzM., BrunkhorstR.C-reactive protein and chronic Chlamydia pneumoniae infection—long term predictors for cardiovascular disease survival in patients on peritoneal dialysis.Nephrol Dial Transplant2001; 16: 809–15.
9.
KimmelP.L., PhillipsT.M., SimmensS.J., PetersonR.A., WeihsK.L., AlleyneS.Immunologic function and survival in hemodialysis patients.Kidney Int1998; 54: 236–44.
10.
BologaR.M., LevineD.M., ParkerT.S., CheighJ.S., SeurD., StenzelK.H.Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.Am J Kidney Dis1998; 32: 107–14.
11.
KimH., BologaR., ParkerT., LevineD., CheichJ.S., StenzelK.Serum IL-6 level as an indicator of survival outcome in CAPD patients (Abstract).J Am Soc Nephrol1999; 10: 1248.
12.
ZoccaliC., BenedettoF.A., MallamaciF., TripepiG., FermoI., FocáA.Inflammation is associated with carotid atherosclerosis in dialysis patients.J Hypertens2000; 18: 1207–13.
13.
StenvinkelP., HeimbürgerO., LindholmB., KaysenG.A., BergströmJ.Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome).Nephrol Dial Transplant2000; 15: 953–60.
14.
StenvinkelP.Inflammatory and atherosclerotic interactions in the depleted uremic patient.Blood Purif2001; 19: 53–61.
15.
ChungS.H., LindholmB., LeeH.B.Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival.Perit Dial Int2000; 20: 19–26.
16.
YeunJ.Y., KaysenG.A.Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin and peritoneal dialysis patients.Am J Kidney Dis1997; 30: 923–7.
17.
HaubitzM., BrunkhorstR., WrengerE., FroeseP., SchulzeM., KochK.M.Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy.Perit Dial Int1996; 16: 158–62.
18.
TakahashiT., KubotaM., NakamuraT., EbiharaI., KoideH.Interleukin-6 gene expression in peripheral mono-nuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis.Ren Fail2000; 22: 345–54.
19.
LibettaC., De NicolaL., RampinoT., De SimoneW., MemoliB.Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation.Kidney Int1996; 49: 506–11.
20.
PasceriV., WillersonJ.T., YehE.T.H.Direct proinflammatory effect of C-reactive protein on human endothelial cells.Circulation2001; 102: 2165–8.
21.
HeimbürgerO., StenvinkelP., BerglundL., TranæusA., LindholmB.Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.Nephron1996; 72: 135–44.
22.
BartensW., NauckM., SchollmeyerP., WannerC.Elevated lipoprotein(a) and fibrinogen levels [corrected] increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients.Perit Dial Int1996; 16: 27–33.
23.
BhagatK., VallanceP.Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo.Circulation1997; 96: 3042–7.
24.
TintutY., PatelJ., ParhamiF., DemerL.L.Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway.Circulation2000; 102: 2636–42.
25.
HuberS.A., SakkinenP., ConzeD., HardinN., TracyR.Interleukin-6 exacerbates early atherosclerosis in mice.Arterioscler Thromb Vasc Biol1999; 19: 2364–7.
26.
RidkerP.M., RifaiN., StampferM.J., HennekensC.H.Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.Circulation2000; 101: 1767–72.
27.
StenvinkelP.Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure.Blood Purif2001; 19: 143–51.
28.
KoppleJ.D., GreeneT., ChumleaW.C., HollingerD.L., MaroniB.J., MerrillD.Relationship between GFR and nutritional status—results from the MDRD study.Kidney Int2000; 57: 1688–703.
29.
StenvinkelP., HeimbürgerO., PaultreF., DiczfalusyU., WangT., BerglundL.Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure.Kidney Int1999; 55: 1899–911.
30.
KaizuY., KimuraM., YoneyamaT., MiyajiK., HibiI., KumagaiH.Interleukin-6 may mediate malnutrition in chronic hemodialysis patients.Am J Kidney Dis1998; 31: 93–100.
31.
GuttridgeD.C., MayoM.W., MadridL.V., WangC.Y., BaldwinA.S.NF-κB–induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia.Science2000; 289: 2363–5.
32.
MitchW.E., DuJ., BaileyJ.L., PriceS.R.Mechanisms causing muscle proteolysis in uremia: the influence of insulin and cytokines.Miner Electrolyte Metab1999; 25: 216–19.
33.
AguileraA., CodoceoR., SelgasR., GarciaP., PicornellM., DiazC.Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients. Their relationship with nutritional parameters.Nephrol Dial Transplant1998; 13: 1476–83.
34.
GrunfeldC., ZhaoC., FullerJ., PollockA., MoserA., FriedmanJ.Endotoxin and cytokines induce expression of leptin, the ob gene product in hamsters. A role for leptin in the anorexia of infection.J Clin Invest1996; 97: 2152–7.
35.
ChurchillD.N., ThorpeK.E., NolphK.D.A., KeshaviahP.R., OreopoulosD.G., PagéD.Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. the Canada–U.S.A. (CANUSA) Peritoneal Dialysis Study Group.J Am Soc Nephrol1998; 9: 1285–92.
36.
WangT., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Increased peritoneal permeability is associated with decreased fluid and small solute removal and higher mortality in CAPD patients.Nephrol Dial Transplant1998; 13: 1242–9.
37.
SelgasR., Fernandez–ReyesM.J., BosqueE., BajoM.A., BorregoF., JimenezC.Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study.Am J Kidney Dis1994; 23: 64–73.
38.
CombetS., MiyataT., MoulinP., PouthierD., GoffinF., DevuystO.Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis.J Am Soc Nephrol2000; 11: 717–28.
39.
StenvinkelP.Endothelial dysfunction and inflammation—is there a link?Nephrol Dial Transplant2001; 16: 1968–71.
40.
SchindlerR., DinarelloC.A., KochK.M.Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells.Cytokine1995; 7: 526–33.
41.
FukuzawaM., SatohJ., SagaraM., MutoG., MutoY., NishimuraS.Angiotensin-converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo.Immunopharmacology1997; 36: 49–55.
42.
TsutamotoT., WadaA., MaedaK., MabuchiN., HayashiM., TsutsuiT.Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure.J Am Coll Cardiol2000; 35: 714–21.
IkonomidisI., AndreottiF., EconomouE., StefanidisC., ToutouzasP., NihoyannopoulosP.Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.Circulation1999; 100: 793–8.
45.
RidkerP.M., CushmanM., StampferM.J., RussellP.T., HennekensC.H.Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men.N Engl J Med1997; 336: 973–9.
46.
LivioM., BenigniA., ViganoG., MeccaG., RemuzziG.Moderate doses of aspirin and risk of bleeding in renal failure.Lancet1986; 1: 414–16.
47.
ChungS.H., StenvinkelP., BergströmJ., LindholmB.Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve?Perit Dial Int2000; 20(Suppl 5): S57–67.
48.
KoppleJ.D., BernardD., MessanaJ., SwartzR., BergströmJ., LindholmB.Treatment of malnourished CAPD patients with an amino acid based dialysate.Kidney Int1995; 47: 1148–57.
49.
NiebauerJ., VolkH.D., KempM., DominguezM., SchumannR.R., RauchhausM.Endotoxin and immune activation in chronic heart failure: a prospective cohort study.Lancet1999; 353: 1838–42.
50.
GrimbleR.F.. Nutritional modulation of cytokine biology.Nutrition1998; 14: 634–40.
51.
Witko–SarsatV., FriedlanderM., KhoaT.N., Capeillére–BlandinC., NguyenA.T., CanteloupS.Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol1998; 161: 2524–32.
52.
DevarajS., JialalI.Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients.Free Radic Biol Med2000; 29: 790–2.
53.
UppritchardJ.E., SutherlandW.H.F., MannJ.I.Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes.Diabetes Care2000; 23: 733–8.
54.
IslamK.N., O'ByrneD., DevarajS., PalmerB., GrundyS.M., JialalI.Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy.Atherosclerosis2000; 150: 217–24.
55.
BoazM., SmetanaS., WeinsteinT., MatasZ., GafterU., IainaA.Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.Lancet2000; 356: 1213–18.
56.
Wieczorowska–TobisK., BreborowiczA., WitowskiJ., MartisL., OreopoulosD.G.Effect of vitamin E on peroxidation and permeability of the peritoneum.J Physiol Pharmacol1996; 47: 535–43.
